Hot Topics in the Management of Advanced Non-Small Cell Lung Cancer: Expert Insights on Recent Advances
Release date 04-03-2021
Expiration date 04-03-2022
The management of advanced non-small cell lung cancer (NSCLC) is changing rapidly, with advances in genomic testing, new precision medicines, and innovative immunotherapeutic strategies. Gain expert insights into some of the most pressing questions related to molecular diagnostics, integration of emerging targeted therapies for rare molecular drivers into clinical practice, and promising strategies to enhance immune checkpoint inhibition.
Daniel S.W. Tan, MBBS, MRCP, PhD, FAMS | Chair
National Cancer Centre Singapore
Daniel Tan is a Senior Consultant Medical Oncologist at the Division of Medical Oncology, National Cancer Centre Singapore (NCCS), an Associate Professor at Duke-National Medical School, and a Senior Clinical-Scientist at the Genome Institute of Singapore. He is also Deputy Head of the Division of Clinical Trials and Epidemiological Sciences, and Director of the Experimental Cancer Therapeutics Unit (Phase I Unit) at NCCS. Dr Tan’s research interests are in thoracic and head and neck oncology, and cancer drug development. His work is focused on improving the understanding of determinants of response and resistance to targeted therapy and immunotherapy. He has published more than 100 peer-reviewed articles, many in high impact-factor journals. He has been the recipient of several national and international awards for his research, including the ASCO Merit Award twice, and in 2019, the IASLC Daniel C. Idhe Lectureship Award for Medical Oncology. Dr Tan serves as Associate Editor for the J Thoracic Oncol and is the conference co-chair for the World Conference in Lung Cancer (WCLC) in 2020, and the track chair for translational research at ESMO 2021.
Herbert Ho Fung Loong, MD
The Chinese University of Hong Kong
Hong Kong SAR, China
Dr Herbert H. Loong holds joint appointments as Clinical Assistant Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase 1 Clinical Trials Centre at The Chinese University of Hong Kong (CUHK). He is also the current and founding convenor of the Prince of Wales Hospital Adult Sarcoma Multidisciplinary Team. Dr Loong obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada, with a special focus on experimental therapeutics. His clinical and research interests also include sarcoma medical oncology, thoracic oncology, and health economics. Dr Loong is a recipient of the European Cancer Congress Fellowship Grant (2013), the ASCO Annual Meeting Merit Award (2014), and the Hong Kong College of Physicians Young Investigators’ Award (2014). Nominated by patients and their caregivers, Dr Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018.
Terufumi Kato, MD
Department of Thoracic Oncology
Kanagawa Cancer Center
Terufumi Kato, MD, is a Chief Physician at the Kanagawa Cancer Center in Yokohama, Japan. Dr Kato received his medical degree from the Faculty of Medicine at Kyoto University in Japan in 1991. He then served his residency in general practice and internal medicine at Tenri Hospital in Nara, Japan, after which he joined as staff physician in the department of respiratory medicine of the hospital. He completed an advanced clinical fellowship in medical oncology at the National Cancer Center Hospital in Tokyo, and a research fellowship at the National Cancer Center Research Institute, also in Tokyo. He is a member of several international societies, including ASCO, ESMO, and IASLC, and is also a committee or faculty member for the Japanese Society of Medical Oncology, Japanese Lung Cancer Society and Japanese Respiratory Society. One of his main research fields is clinical research of medical treatments for lung cancer, especially concerning genomic diagnosis, drug therapy for oncogene-driven cancers, and immunotherapy. Another field of interest is the management of drug-induced pneumonitis in both lung cancer and other tumors.
- When is the right time to use NGS-based liquid biopsy in advanced NSCLC? | Herbert Ho Fung Loong, MD
- Integrating new targeted therapy for NSCLC with rare oncogenic drivers into clinical practice | Terufumi Kato, MD
- Enhancing immune checkpoint inhibition with bifunctional antibodies | Daniel S.W. Tan, MD, PhD
This educational activity is designed specifically for medical oncologists, pulmonologists, pathologists, and other healthcare providers involved in the management of patients with advanced NSCLC.
Upon completion of this educational activity, participants should be able to:
- Compare and contrast the use of tissue-based NGS with blood-based NGS to identify uncommon molecular drivers in advanced NSCLC
- Evaluate the efficacy and safety of new targeted therapies in patients with advanced NSCLC and rare driver mutations, and determine how to incorporate new options into clinical practice.
- Identify new strategies to enhance the efficacy of immune checkpoint inhibition in NSCLC, including bifunctional antibodies targeting PD-L1 and TGFβ pathways
Provided by ACE Oncology.
This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany.
This enduring online activity, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by ACE Oncology for a certified live event, this activity does not offer continuing education credit.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Herbert Ho Fung Loong has served as an advisor or consultant for Boehringer Ingelheim, Celgene, Eli Lilly, Illumina, Novartis, Merck Serono, and Takeda. He has served as a speaker or a member of a speakers bureau for AbbVie, Bayer, Eisai, Eli Lilly, Guardant Health, and Novartis. Prof Loong has received grants for clinical research from MSD, Mundipharma, and Novartis. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.
Terufumi Kato has served as an advisor or consultant for Amgen, AstraZeneca, Chugai, Eli Lilly, Merck Biopharma, MSD, Ono, Pfizer, and Takeda. He has served as a speaker or a member of a speakers bureau for AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, Merck Biopharma, MSD, Nippon Kayaku, Novartis, Ono, Pfizer, Shionogi, Taiho, and Takeda. Dr Kato has received grants for clinical research from AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Chugai, Eli Lilly, Merck Biopharma, MSD, Novartis, Ono, Pfizer, Regeneron, and Taiho. His spouse is employed at Eli Lilly. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.
Daniel Tan has served as an advisor or consultant for Novartis, Bayer, Boehringer Ingelheim, Celgene, AstraZeneca, EliLilly, and Loxo. Prof Tan has received grants for clinical research from Novartis, AstraZeneca, Pfizer, and Bayer. Any unlabeled/unapproved uses of drugs or products referenced in his presentation will be specified.
The employees of ACE Oncology have disclosed no relevant financial relationships.
ACE Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to ACE Oncology’s policy. ACE Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.